Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enzon Pharmaceuticals ( (ENZN) ) has shared an announcement.
On March 10, 2026, Enzon Pharmaceuticals entered into a Ninth Amendment to its Section 382 Rights Agreement, extending the Final Expiration Date of the shareholder rights from March 11, 2026 to noon, New York City time, on March 18, 2026. The company’s management stated this adjustment was in the best interests of Enzon and its stockholders, and no other terms of the rights plan were changed.
On March 11, 2026, Enzon also announced that it had extended the expiration date of its exchange offer for Series C Non-Convertible Redeemable Preferred Stock, with holders now having until 5:00 p.m. Eastern on March 16, 2026 to exchange into common stock unless further extended. These actions come as Enzon advances a planned merger with Viskase, supported by a previously filed Form S-4 registration statement outlining the proposed combined company for investors and other stakeholders.
More about Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc. operates in the pharmaceutical sector, with its capital structure including Series C Non-Convertible Redeemable Preferred Stock and common stock. The company is currently engaged in a proposed merger with Viskase Companies, Inc., for which it has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission containing financial information about the combined entity.
Average Trading Volume: 72,882
Technical Sentiment Signal: Sell
Current Market Cap: $4.23M
See more insights into ENZN stock on TipRanks’ Stock Analysis page.